Core Viewpoint - The company has launched the PixelPeel™ safe laser skin rejuvenation treatment to meet the growing demand for safe, effective, and short-recovery skin renewal procedures, initially debuting in North America with plans for global expansion [1] Group 1: Product Details - PixelPeel™ utilizes clinically recognized gold standard laser energy combined with pixel-level precision and Alma's proprietary MotionSync™ technology to ensure a safe, uniform, and controllable treatment process [1] - The treatment effectively improves skin texture, tone, and brightness, making it suitable for both first-time users and those seeking long-term skin maintenance [1] - The solution offers high clinical efficacy with a short recovery period and is applicable to various skin types [1] Group 2: Market Impact - The company believes that PixelPeel™ will provide advanced treatment options that align with current market demands, offering a more convenient and efficient skin care experience for medical institutions and consumers [1] - The comprehensive application of PixelPeel™ in Alma Pixel™ and Alma Hybrid devices aims to expand the market coverage of existing equipment systems, thereby increasing procurement and usage rates [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 自願公告 本公告乃由復銳醫療科技有限公司（「本公司」）自願發佈。 本公司欣然宣佈推出PixelPeel™安全激光煥膚治療方案（「該方案」），旨在滿足對 安全、有效且恢復期短的皮膚煥新療程日益增長的需求，並全面運用在新一代 Alma Pixel™及Alma Hybrid設備系統中。該方案已於北美首發，並計劃逐步推向 全球市場。 於本公告日期，本公司董事會成員包括執行董事劉毅先生及Lior Moshe DAYAN 先生及李家宏先生；非執行董事吳以芳先生及馮蓉麗女士；獨立非執行董事方香 生先生、陳志峰先生、陳怡芳女士及廖啟宇先生。 PixelPeel™運用臨床公認的黃金標準激光能量，結合像素級精準度，並搭載Alma 專利MotionSync™技術，確保治療過程安全、 ...

Core Viewpoint - Suzhou Mediston Medical Technology Co., Ltd. reported a net profit of 28.33 million yuan for the first half of 2025, attributing the increase in profitability to the divestment of its photovoltaic business and a return to its core medical operations, which improved cash flow [1][1]. Group 1: Financial Performance - The company achieved a net profit of 28.33 million yuan in the reporting period [1]. - The improvement in profitability is linked to the completion of the photovoltaic business disposal in January 2025 [1]. Group 2: Business Strategy - Mediston is focusing on the elderly care robot sector, conducting extensive empirical research in nursing homes and hospitals to address emotional, medical, and care needs of the elderly [1][1]. - The company aims to position itself as a supplier of comprehensive smart elderly care solutions and a developer of real application scenarios, differentiating itself from manufacturers that directly produce robots [1]. Group 3: Technological Development - Mediston is developing specialized small models for the elderly care sector based on general large models from companies like Huawei and Alibaba, utilizing clinical medical knowledge bases [1]. - The company is creating a smart elderly care information management system to efficiently operate diverse robotic hardware resources under a centralized command [1]. Group 4: Collaborations and Investments - Mediston has established partnerships with institutions such as the Chinese Academy of Sciences, Huawei, and others to advance research and innovation in elderly care robots and artificial intelligence [1]. - In July 2025, the company increased its stake in its subsidiary, Suzhou Youmai Robot Co., Ltd., to 70%, highlighting its strategic emphasis on the elderly care robot business [1].

天眼查商业履历信息显示，塞力斯医疗科技集团股份有限公司，成立于2004年，位于武汉市，是一家以 从事研究和试验发展为主的企业。企业注册资本19095.2305万人民币，实缴资本3800万人民币。公司法 定代表人为温伟。 金融界消息 截至2025年8月25日收盘，塞力医疗（603716）报收于34.67元，上涨9.99%，换手率 23.65%，成交量45.18万手，成交金额15.37亿元。 资金流向方面，今日主力资金净流入1.87亿元，占比成交额12.17%。其中，超大单净流入2.74亿元、占 成交额17.85%，大单净流出8742.93万元、占成交额5.69%，中单净流出流出11779.00万元、占成交额 7.66%，小单净流出6917.30万元、占成交额4.5%。 塞力医疗最新一期业绩显示，截至2025一季报，公司营业总收入2.87亿元、同比减少40.75%，归属净利 润1432.09万元，同比减少553.66%，扣非净利润2846.33万元，同比减少3228.81%，流动比率1.931、速 动比率1.591、资产负债率58.57%。 通过天眼查大数据分析，塞力斯医疗科技集团股份有限公司共对外投资了70家企 ...

Group 1 - Shanghai Hantong Medical Technology Co., Ltd. recently completed a "Pre-A+ round" financing, raising several tens of millions of RMB, with Shuncheng Capital as the investor [1] - The company was established in 2022, has a registered capital of 5.105429 million RMB, and is primarily engaged in research and experimental development [1] - The company has invested in 5 other enterprises and holds 30 trademark registrations and 26 patents, along with 4 administrative licenses [1] Group 2 - The legal representative of Shanghai Hantong Medical Technology Co., Ltd. is Zhao Wanjin, and the company is located in Shanghai [1] - The shareholders include Zhao Wanjin, Hunan Dacheng Caizhi SME Venture Capital Partnership, Beijing Tongchuang Shared Medical Equity Investment Fund Partnership, Shanghai Hanmai Cheng Medical Technology Partnership, and Shanghai Hanmai Rong Medical Technology Partnership [1]

Summary of Key Points Core Viewpoint - The article highlights the recent stock reduction activities of two A-share listed companies, indicating a cautious sentiment in the market as no companies reported share increases on August 24. Group 1: Company Actions - Juguang Technology's shareholders plan to reduce their holdings by no more than 3.48% of the company's shares [2] - Ailong Technology's controlling shareholder, actual controller, and chairman intend to collectively reduce their holdings by no more than 1.69% of the company's shares [2]

Core Viewpoint - Suzhou Mediston Medical Technology Co., Ltd. (referred to as "Mediston") reported a significant turnaround in its financial performance for the first half of 2025, achieving a net profit of 28.33 million yuan, compared to a loss in the same period last year [1] Financial Performance - The company achieved operating revenue of 135 million yuan and a total profit of 31.14 million yuan during the reporting period [1] - The net profit attributable to shareholders was 28.33 million yuan, marking a return to profitability compared to the previous year [1] Technological Advancements - Mediston completed the domestic software localization and innovation transformation, ensuring compatibility with major domestic hardware and software platforms, meeting national technology requirements [1] - The products are now compatible with Huawei's Kunpeng series servers and support various domestic operating systems, including Tongxin UOS and Kylin [1] - The company has optimized its database compatibility with major domestic databases, ensuring efficient and stable operation in a secure environment [1] AI and Product Development - The company upgraded its anesthesia, critical care, and emergency systems with AI integration and deep fusion with the DeepSeek model [1] - The intelligent doctor assistant module provides clinical decision support, helping doctors formulate precise treatment plans based on patient history and examination data [1] Strategic Collaborations - Mediston's health and wellness robot project has initiated strategic collaborations with multiple medical institutions, focusing on the application of embodied intelligent robots in the health and elderly care sectors [2]

Core Viewpoint - The financial performance of Sichuang Medical (300078) shows significant revenue growth but also highlights challenges in profitability and cash flow management [1][3]. Financial Performance Summary - Total revenue for the first half of 2025 reached 545 million yuan, a year-on-year increase of 37.32% compared to 397 million yuan in 2024 [1]. - The net profit attributable to shareholders was -51.83 million yuan, improving by 76.74% from -22.3 million yuan in the previous year [1]. - The gross profit margin decreased to 8.57%, down 44.26% from 15.38% in the previous year [1]. - The net profit margin improved to -9.85%, a significant increase of 82.68% from -56.86% in 2024 [1]. - The total of selling, administrative, and financial expenses was 86.6 million yuan, accounting for 15.89% of revenue, a decrease of 49.01% year-on-year [1]. Cash Flow and Debt Management - Cash and cash equivalents increased by 151.92% due to increased borrowings [3]. - The company reported a significant reduction in interest-bearing debt, down 68.91% to 339 million yuan [1]. - Operating cash flow showed a decline of 28.0%, attributed to increased tax payments related to property disposals [3]. Operational Insights - Accounts receivable accounted for 50.24% of total revenue, indicating a large volume of outstanding payments [1]. - The company disposed of investment properties, which significantly impacted both revenue and costs, with a revenue contribution of 293.46 million yuan from property disposals [3]. - Research and development expenses decreased by 50.99%, reflecting a reduction in R&D personnel in the medical sector [3]. Historical Performance Context - The company's historical return on invested capital (ROIC) has been weak, with a median of 4% over the past decade and a particularly poor ROIC of -32.19% in 2024 [4]. - The company has experienced four years of losses since its listing, indicating challenges in maintaining profitability [4].

Group 1 - Dongfang Zhenxuan denies the departure of former CEO Sun Dongxu, stating he is on leave and has been working as a consultant since December 2023 [3] - For the fiscal year 2025, Dongfang Zhenxuan reported revenue of 4.392 billion yuan, a decrease of 32.7% from 6.5 billion yuan in the previous year, with a net profit of 60.745 million yuan [3] - Excluding the financial impact from the sale of Huizhong, the net profit from continuing operations increased by 30% from 104 million yuan in fiscal year 2024 to 135 million yuan in fiscal year 2025 [3] Group 2 - Alibaba has restructured its business into four main divisions: Alibaba China E-commerce Group, Alibaba International Digital Commerce Group, Cloud Intelligence Group, and "All Other" businesses, marking the end of the previous "1+6+N" structure [6] - Starbucks has requested potential bidders to submit non-binding offers for a stake in its China business within two weeks, inviting private equity firms and other interested parties to a management meeting [6] - Evergrande Real Estate Guangdong Company has been ruled for bankruptcy liquidation, entering the legal bankruptcy process [7] Group 3 - Xiaomi's smartphone market share in Africa has increased by 32%, capturing 14% of the market, while Honor has seen the largest growth, with a 161% increase [22][23] - The total box office for the summer movie season in 2025 has surpassed 10.5 billion yuan, with top films including "Nanjing Photo Studio" and "Longan's Lychee" [23] - As of the end of July 2025, the national passenger car inventory was 3.29 million units, a decrease of 30,000 units from the previous month and 40,000 units from July 2024, indicating a positive trend in inventory reduction [25]

Core Insights - Medical technology company Yidu Tech (02158) saw its stock rise over 5%, currently trading at 6.65 HKD with a transaction volume of 69.47 million HKD [1] Group 1: Product Development and Innovations - Yidu Tech, in collaboration with Guangdong Medical University Affiliated Hospital, launched the "Multimodal Disease Database for Vascular Diseases" and "Meiyi Intelligent Body" at the 2025 Academic Annual Meeting of the Guangdong Provincial Hospital Association [1] - The "Meiyi Intelligent Body" serves as a core technology platform, marking Yidu Tech's first application of its large model in the medical aesthetics field [1] Group 2: Digital Health Initiatives - At the 2025 Digital Therapy Conference, Yidu Tech presented its achievements in the "2+3" diabetes management project in Hainan, highlighting its role as an AI medical enterprise [1] - Since the pilot program began in 2023, Yidu Tech has collaborated closely with Ling Shui County, achieving a 99.09% inclusion rate of managed patients into systematic care, with fasting blood glucose and glycated hemoglobin compliance rates improving by 18.63% and 4.68%, respectively, surpassing the provincial average [1] - Following Ling Shui, the company plans to extend its AI medical innovations to cities such as Sanya, Wanning, Qionghai, and Wenchang, with an aim to expand digital therapy services for hypertension and other chronic diseases, targeting coverage for over 100,000 regional patients by 2025 [1]